Insight into pharmaceutical deals and trends

In Vivo

How To Obtain Effective Relief When A Global Pandemic Disrupts Your Supply Chain

The COVID-19 pandemic is disrupting global supply chains and companies need effective tools to manage the related contract disputes. Sidley Austin partner Dorothee Schramm and senior associate Katie von der Weid, both specialized in international commercial disputes, provide tips to help companies manage the situation.

Topic Coronavirus Business Strategies Deals

Generics Bulletin

Coherus Is Confident After US Ranibizumab Filing

Having seen its development partner Bioeq file with the FDA in December last year, Coherus is confident that it will be a leader in the US biosimilar ranibizumab market targeting Lucentis.

Topic Biosimilars Deals

Generics Bulletin

Biocon Biologics Gets True North Investment

Private equity group True North continues to back the Biocon group and is picking up a minority stake in Biocon Biologics in a deal that values the subsidiary at $3bn. Separately, another subsidiary, Biocon Biosphere, has also been set up as part of efforts to unlock the full potential of the business.

Topic Deals Strategy

Generics Bulletin

Pfizer Reports 80% Biosimilars Growth In Q3

Pfizer has reported 80% growth in its global biosimilars business for the third quarter of 2020, on the back of recent oncology launches. Though the company’s sterile injectables saw a slight drop in business, Pfizer’s biopharma business saw 4% growth.

Topic Coronavirus Biosimilars Deals

Scrip

2020’s Most Significant Cancer Deals

Gain insights into the oncology deals making headlines with exclusive reporting and analysis from Scrip. Explore a snapshot view of the year’s biggest oncology deals so far, in a convenient infographic and go deeper into two major cancer deals that occurred in September with your free article pack.    

Topic Cancer Deals

Pink Sheet, Scrip, In Vivo

Gene Therapy eBook

Keep up with advances in the critically important, emerging area of gene therapy. This transformative new category of medicines has the potential to treat more diseases – including complex and rare diseases – with longer-lasting effects than traditional medicines.

Topic Research & Development Deals

Generics Bulletin

Sun Finds US ‘Challenging’

Sun Pharma’s Indian domestic operations posted strong sales in the third quarter, but this was not enough to prevent the company from reporting a 26% tumble in consolidated net profit in the face of a “challenging” US generics market and slow approvals for complex products.

Topic Deal trends